Shire (company)

Shire (company)
Name	Shire
Type	Public
Industry	Pharmaceuticals
Founded	1986
Fate	Acquired by Takeda Pharmaceutical Company
Headquarters	Basingstoke, England
Key people	Flemming Ornskov; Angus Russell; Adam Fennessy
Products	Adderall XR; Vyvanse; Lialda; Cinryze
Revenue	(historic) £5.8 billion (2016)
Employees	~25,000 (2016)

Shire (company)

Shire was a multinational biopharmaceutical company founded in 1986 and headquartered in Basingstoke, England, known for specialty medicines for rare diseases, neuroscience, and gastrointestinal disorders. The company grew through acquisitions and internal research to become a major player in orphan drugs and specialty pharmaceuticals before its 2019 acquisition by Takeda Pharmaceutical Company. Shire’s portfolio and corporate actions intersected with a wide array of pharmaceutical companies, regulatory agencies, and healthcare institutions worldwide.

History

Shire was established in 1986 by Ned Johnson and Peter Schuster as a venture focusing on commercializing biotechnology assets, expanding rapidly through interactions with firms such as Merck, GlaxoSmithKline, AstraZeneca, and Johnson & Johnson. In the 1990s Shire diversified via transactions with Eli Lilly and Company, Pfizer, and Novartis, and its strategy pivoted toward specialty pharmaceuticals under leadership linked to the broader industry network including executives from Roche and Bayer. During the 2000s and 2010s the company completed notable deals with ViroPharma, Jerini, Movetis, and NPS Pharmaceuticals, aligning Shire with the orphan drug movement championed by actors such as Genzyme and Amgen. Shire’s public listings and investor relations engaged markets on the London Stock Exchange and NASDAQ, and its corporate trajectory culminated in the purchase by Takeda Pharmaceutical Company in 2019, a transaction involving regulatory review by authorities including the European Commission and the US Department of Justice.

Products and Therapeutic Areas

Shire’s portfolio emphasized treatments for rare diseases, neuroscience, and gastroenterology, with key brands comparable in market presence to therapies from Celgene, Biogen, Regeneron Pharmaceuticals, and Gilead Sciences. Central products included stimulant and non-stimulant medicines for attention-deficit/hyperactivity disorder with peers like Eli Lilly’s offerings and Johnson & Johnson’s psychiatric portfolio, alongside orphan therapeutics such as C1 esterase inhibitor products used in hereditary angioedema in the same clinical domain as agents developed by CSL Limited and BioCryst Pharmaceuticals. Gastroenterology assets competed with medicines from Takeda and GlaxoSmithKline for inflammatory bowel disease and other conditions, while enzyme replacement and hematology programs were positioned near initiatives from Sanofi and Novo Nordisk.

Research and Development

Shire invested in both internal discovery and external collaborations, forming alliances with academic centers like University of Oxford, Harvard Medical School, and institutes such as Massachusetts General Hospital and Broad Institute. R&D efforts targeted orphan indications mirroring strategies used by Alexion Pharmaceuticals and Vertex Pharmaceuticals, leveraging clinical development pathways overseen by regulators including the Food and Drug Administration and the European Medicines Agency. Shire’s pipeline included biologics, small molecules, and gene therapy collaborations akin to programs at Bluebird Bio and Spark Therapeutics, and it pursued pediatric and rare-disease trials registered with networks similar to ClinicalTrials.gov and coordinated with patient groups such as National Organization for Rare Disorders and European Organisation for Rare Diseases.

Manufacturing and Operations

Shire maintained manufacturing sites and partnerships with contract manufacturers comparable to Catalent and Lonza, with quality systems subject to inspections by agencies like the US Food and Drug Administration and national regulators across Japan, Canada, and the European Union. Its supply chain logistics paralleled the global distribution networks of McKesson and Cardinal Health, and it operated commercial and medical affairs teams engaging stakeholders at hospitals such as Mayo Clinic and Cleveland Clinic and purchasers including NHS England and UnitedHealth Group.

Corporate Governance and Leadership

Shire’s board and executive leadership featured figures with backgrounds at multinational corporations and financial institutions including Morgan Stanley and Goldman Sachs, and leaders who had prior roles at companies like AstraZeneca and GlaxoSmithKline. Governance practices were influenced by corporate law precedents from jurisdictions such as England and Wales and Delaware, and its investor relations engaged sovereign wealth and asset managers such as BlackRock and Vanguard Group.

Mergers and Acquisitions

Mergers and acquisitions were central to Shire’s growth strategy, with landmark transactions involving companies like Transkaryotic Therapies, Biomarin Pharmaceutical, NPS Pharmaceuticals, Baxalta (in competing consolidation narratives), and corporate interactions with bidders and advisors from Goldman Sachs and JP Morgan. Acquisition activity placed Shire among consolidation trends alongside Takeda, Pfizer, and AbbVie, and its own acquisition by Takeda Pharmaceutical Company refashioned global specialty-pharma market structure, prompting asset divestitures overseen by competition authorities including the Federal Trade Commission and the European Commission.

Controversies and Legal Issues

Shire faced controversies and litigation related to pricing, promotional practices, and regulatory compliance similar to disputes encountered by Mylan, Martin Shkreli-era controversies in the industry, and class actions seen in cases involving Valeant Pharmaceuticals. Legal matters involved settlements and court reviews in jurisdictions such as United States District Court and the High Court of Justice in England, and interactions with enforcement bodies including the US Department of Justice and the UK Serious Fraud Office. Additionally, debates over tax inversion strategies and corporate domicile choices connected Shire to public policy discussions involving legislators from US Congress and economic commentators at institutions like the Brookings Institution.

Category:Pharmaceutical companies Category:Biopharmaceutical companies